Immunotherapy for Cancer in Germany

1. Content Strategy

Primary keyword: immunotherapy in Germany

Secondary keywords:

cancer immunotherapy in Germany
checkpoint inhibitors (pembrolizumab, nivolumab)
Keytruda in Germany cost
CAR-T and bispecific antibodies
dendritic cell therapy in Germany
immunotherapy cost in Germany

Search intent: Commercial-investigational. Patients and families want to know:

whether immunotherapy suits their cancer
which kind
whether German hospitals offer something unavailable at home
what it costs
where to go

Many are also searching for dendritic cell "vaccines" offered by private clinics.

Target audience: International adults with solid tumours or blood cancers, and their families. Many already receive standard treatment at home and want a second opinion or access to newer drugs.

Main content angle: Immunotherapy is now part of standard care for many cancers. The important questions are which approved drug fits the cancer, stage and biomarkers, and whether treatment can continue at home. Germany offers approved immunotherapies at certified cancer centres, molecular testing and clinical trials. The page clearly separates these from dendritic cell therapies sold by private clinics, which the EMA warned about in 2025. Costs are rebuilt from Germany's public drug price.

Key issues identified in the existing CRR page and corrected in the Vaidam version:

Fabricated success rates removed. "Melanoma 70–80%", "Lung cancer 50–60%", "CAR T-cell therapy 80–90%" and "an efficacy of 70–90% for various cancers" have no source and no definition. They are replaced with named trial results. For example, 43% of patients were alive 10 years after nivolumab plus ipilimumab for advanced melanoma (CheckMate 067).
Dendritic cell therapy presented as standard. The existing page lists dendritic cell vaccines as "standard options" and "commonly used" for melanoma. No dendritic cell therapy is currently approved in the EU. In March 2025, the EMA warned patients against unregulated dendritic cell therapies, noting that some German clinics offer them under national pathways. A warning section replaces the promotion.
Factual error corrected. The page says sipuleucel-T is an approved vaccine in Germany. Its EU authorisation was withdrawn in May 2015.
Centre list replaced. The existing "leading centres" table includes three private clinics offering dendritic cell or other unapproved therapies alongside Charité and Heidelberg. It is replaced with certified university centres described with verified facts.
Cost table rebuilt. The existing table gives the same €375,000–€420,000 for checkpoint inhibitors in every cancer and €20,000–€38,000 for dendritic cell therapy. Germany's public price for pembrolizumab (Keytruda) is €2,039.27 per 100 mg, which is about €4,080 per standard 200 mg dose and about €69,300 for a year of treatment every 3 weeks.
"Expert surgeons" heading and "thousands of successful immunotherapy cases" removed. These are unsupported and inaccurate, as immunotherapy is given by oncologists.
CAR-T and bispecific antibodies updated and linked to the dedicated CAR-T page.
Competitor-style content and promotional wording removed: "global leader", "at the forefront", "state-of-the-art", "cutting-edge", "robust", "paradigm shift", "journey"
Empty FAQs fixed. Eight FAQ questions on the live page have no visible answers. All 10 FAQs now have answers.

2. SEO Metadata

Title: Immunotherapy in Germany | Cancer Options, Centres and Cost

Meta description: Cancer immunotherapy in Germany: approved checkpoint inhibitors, CAR-T and bispecific antibodies, who benefits, unproven therapies to avoid and estimated costs.

Immunotherapy helps the immune system find and attack cancer. It is now part of standard treatment for many cancers, including melanoma, lung, kidney, bladder, head and neck, some breast, bowel and stomach cancers, and several blood cancers.

Most commonly used: checkpoint inhibitors, such as pembrolizumab (Keytruda), nivolumab (Opdivo) and atezolizumab (Tecentriq), given as a drip into a vein every 3 to 6 weeks.
For some blood cancers: CAR-T cell therapy and bispecific antibodies.
Who benefits depends on the cancer type, stage and biomarkers such as PD-L1, mismatch repair status (MSI) and tumour mutational burden. Not every cancer responds.
Not approved: dendritic cell "vaccines" sold by private clinics. The European Medicines Agency (EMA) warned patients against unregulated dendritic cell therapies in 2025.

Cost: In Germany, pembrolizumab costs about €4,080 per standard dose, given every 3 weeks. Therefore, a year of treatment costs can be about €69,300 for the drug alone. Treatment usually continues at home once a plan is agreed.

This guide explains the types of immunotherapy, which cancers they treat, results, side effects, how to avoid unproven offers, centres and estimated costs.

Types of Immunotherapy

Type	How it works	Examples approved in the EU
Checkpoint inhibitors	Antibodies that release the "brakes" (PD-1, PD-L1, CTLA-4, LAG-3) that stop T cells from attacking cancer.	Pembrolizumab, nivolumab, ipilimumab, atezolizumab, durvalumab, cemiplimab, dostarlimab, relatlimab with nivolumab
CAR-T cell therapy	The patient's T cells are genetically modified to attack a marker on cancer cells.	Products for certain lymphomas, B-cell leukaemia and myeloma (see the CAR-T page)
Bispecific antibodies (T-cell engagers)	Drugs that bind a T cell and a cancer cell at the same time, bringing them together.	Blinatumomab (B-cell leukaemia), teclistamab and others (myeloma), glofitamab and epcoritamab (lymphoma), tarlatamab (small cell lung cancer), tebentafusp (uveal melanoma)
Oncolytic virus	A modified virus injected into tumours that kills cancer cells and stimulates the immune system.	Talimogene laherparepvec (Imlygic) for melanoma that cannot be removed surgically
Cytokines	Immune signalling proteins such as interleukin-2 and interferon.	Largely replaced by checkpoint inhibitors. Now rarely used.
Therapeutic cancer vaccines	Train the immune system against tumour markers. Personalised mRNA vaccines are in clinical trials.	None currently approved in the EU
Dendritic cell therapy	The patient's immune cells are loaded with tumour material in a laboratory and re-injected.	None currently approved in the EU

Which Cancers Are Treated with Immunotherapy?

Cancer	How immunotherapy is used (examples)
Melanoma	Checkpoint inhibitors for advanced disease and after surgery for high-risk melanoma. Imlygic for selected unresectable melanoma.
Non-small cell lung cancer	Checkpoint inhibitors alone (high PD-L1) or with chemotherapy for advanced disease, around surgery for earlier stages, and after chemoradiotherapy.
Small cell lung cancer	Checkpoint inhibitors with chemotherapy. Tarlatamab after earlier treatment.
Kidney cancer	Checkpoint inhibitor combinations, and pembrolizumab after surgery in high-risk disease.
Bladder cancer	Checkpoint inhibitors and enfortumab vedotin with pembrolizumab for advanced disease.
Head and neck cancer	Checkpoint inhibitors for recurrent or metastatic disease.
Triple-negative breast cancer	Pembrolizumab with chemotherapy before and after surgery for early high-risk disease, and with chemotherapy for advanced PD-L1-positive disease.
Bowel, stomach and endometrial cancer	Checkpoint inhibitors, especially for tumours with mismatch repair deficiency (MSI-high). For stomach and oesophageal cancer, with chemotherapy depending on PD-L1.
Liver cancer	Checkpoint inhibitor combinations for advanced disease.
Cervical cancer	Pembrolizumab with chemotherapy or chemoradiotherapy in selected patients.
Lymphoma, leukaemia and myeloma	CAR-T cells and bispecific antibodies. Checkpoint inhibitors for Hodgkin lymphoma.

Where immunotherapy usually does not work well: most pancreatic cancers, most prostate cancers, and bowel cancers without mismatch repair deficiency. Immunotherapy for these is usually offered only in trials or for specific biomarkers.

Biomarker testing

Your team will usually test the tumour for:

PD-L1 (for example, in lung, stomach, head and neck and breast cancer)
mismatch repair deficiency or MSI (bowel, endometrial, stomach and other cancers)
tumour mutational burden in selected cases
driver mutations in lung cancer, such as EGFR or ALK, which usually mean targeted tablets work better than immunotherapy

Results of Immunotherapy

Results depend on the cancer, stage, biomarkers and treatment combination. These examples come from major trials.

Cancer and setting	Trial	Result
Advanced melanoma, first treatment	CheckMate 067 (nivolumab plus ipilimumab)	43% alive at 10 years. Median overall survival 71.9 months.
Advanced non-small cell lung cancer, PD-L1 at least 50%	KEYNOTE-024 (pembrolizumab vs chemotherapy)	31.9% alive at 5 years, vs 16.3% with chemotherapy
Early high-risk triple-negative breast cancer	KEYNOTE-522 (pembrolizumab with chemotherapy before and after surgery)	Improved overall survival compared with chemotherapy alone

How to read these figures:

They come from trials with selected patients and cannot predict an individual result.
Many patients do not respond. In some who do, the response lasts for years.
Responses can take several weeks or months to appear on scans.

Side Effects

Checkpoint inhibitors can cause the immune system to attack healthy organs. These are called immune-related adverse events.

Area	Possible effects
Skin	Rash, itching, loss of skin colour (vitiligo)
Bowel	Diarrhoea, colitis
Hormone glands	Underactive or overactive thyroid, adrenal or pituitary problems, sometimes needing lifelong hormone replacement, and rarely diabetes
Lungs	Pneumonitis (cough, breathlessness)
Liver	Hepatitis, detected on blood tests
Other	Kidney, heart, nerve, muscle or joint inflammation (rare but can be serious)

Most side effects are mild and treatable, often with corticosteroids. Severe reactions occur in a minority of patients, more often with combination treatment. They can appear months after treatment starts or even after it ends, so tell any doctor you see that you have had immunotherapy.

CAR-T cells and bispecific antibodies can also cause cytokine release syndrome and neurological side effects, which need hospital monitoring.

Dendritic Cell Therapy and Other Unproven Offers: A Warning

Some private clinics in Germany offer dendritic cell therapy, "individualised vaccines", or combinations with viruses, hyperthermia and other treatments, often for €20,000 or more.

No dendritic cell therapy is currently approved in the EU. The only one ever approved, sipuleucel-T (Provenge) for prostate cancer, had its EU authorisation withdrawn in May 2015.
In March 2025, the EMA warned that unregulated cell therapies, including dendritic cell therapies, are being marketed to patients in Europe. It stressed that patients should only be offered therapies authorised or approved by a regulator. It noted that some German clinics offer dendritic cell therapies under national rules.
Germany's Paul-Ehrlich-Institut issued a similar warning, listing as warning signs: promises of healing without evidence, commercial "experimental" treatment outside approved trials, no confirmation of approval, and high costs not covered by insurance.

Before paying for any immunotherapy, ask for the drug or product name and check that it is approved by the EMA for your cancer, or that it is part of a registered clinical trial.

What Treatment in Germany Involves for International Patients?

Quality signals

Certified cancer centres. The German Cancer Society (DKG) certifies organ cancer centres, such as lung, skin and breast cancer centres. Certified centres hold weekly tumour boards and are audited each year. German Cancer Aid (Deutsche Krebshilfe) designates Comprehensive Cancer Centres at university hospitals.
Molecular testing. Broad biomarker testing, including through the national Network Genomic Medicine (nNGM) for lung cancer.
Clinical trials. University centres run trials of new immunotherapies, including personalised mRNA vaccines and new bispecific antibodies. Trials are registered in the EU Clinical Trials Register and the German Clinical Trials Register (DRKS).

Typical time in Germany

Treatment	Typical planning
Second opinion and biomarker testing	About 1 to 2 weeks. Molecular results can take longer.
Starting checkpoint inhibitor treatment	First 1 to 2 cycles in Germany (about 3 to 6 weeks) to check tolerance. Treatment can often continue at home under a plan agreed with the German team.
Treatment around surgery	Depends on the plan. For example, several cycles before surgery, the operation, then further cycles.
CAR-T cell therapy	Usually about 2 to 3 months
Bispecific antibodies	The first doses are usually given in hospital because of side effect risks. Later doses are outpatient.

Checkpoint inhibitors are often given for up to 1 to 2 years, so continuing treatment at home is usually the most practical and affordable option.

Hospitals for Immunotherapy in Germany

Check whether a hospital:

is a DKG-certified centre for your cancer type, or part of a Comprehensive Cancer Centre
offers broad biomarker testing
has experience managing immune-related side effects, with specialists in endocrinology, gastroenterology and pulmonology available
offers clinical trials for your cancer
uses only approved drugs or registered trials
has an international patient office that provides written estimates and interpreters

The hospitals below are examples with verified information. This is not a ranking or endorsement.

Hospital	City	Verified information
Thoraxklinik Heidelberg (Lung Cancer Centre at NCT Heidelberg)	Heidelberg	DKG-certified lung cancer centre since 2009. Treats more than 1,000 patients with newly diagnosed lung cancer a year.
Charité – Universitätsmedizin Berlin	Berlin	Its Comprehensive Cancer Centre includes organ cancer centres and participates in the nNGM molecular testing network.
Heidelberg University Hospital, Department of Medicine V	Heidelberg	One of the first centres in Germany to use CAR-T therapy. Has a GMP laboratory that makes CAR-T cells for clinical studies.
University Hospital Würzburg, Department of Medicine II	Würzburg	CAR-T programme since 2016, with more than 100 infusions by March 2023, for lymphoma, ALL and myeloma.

Certifications, specialists and international services change. Vaidam can confirm current details for the hospitals you are considering.

Cost of Immunotherapy in Germany

No single price applies. Cost depends on the drug, dose, number of cycles, how much treatment is given in Germany, and tests and monitoring.

What affects the total cost?

Cost component	Why it varies
Drug	Which drug, single or combination, dose, number of cycles
Biomarker testing	PD-L1, MSI, broad molecular panels
Scans	CT or PET-CT before treatment and every few months
Monitoring	Blood tests for thyroid, liver, kidney and other organ function
Side effects	Treatment of immune-related side effects, sometimes in hospital
Non-medical costs	Accommodation, travel, interpreters, visa

How International Patients Can Prepare?

Medical documents to gather

Pathology report, with tumour type and grade.
Biopsy blocks or slides, for biomarker testing in Germany.
Biomarker results already done, such as PD-L1, MSI or mismatch repair, and molecular panels.
Recent CT, MRI or PET-CT scans (on disc or download link), with reports.
Treatment history, with drugs, cycles, dates and response, including any previous immunotherapy and side effects.
Blood tests, including thyroid, liver and kidney function, and a list of medicines and other conditions, especially autoimmune diseases.

Reports in languages other than English or German may need translation.

Travel and administrative documents

Visa. Most non-EU patients need a visa for medical treatment. Applications usually need the hospital's invitation letter with a cost estimate, proof of funds and health insurance.

Continuing at home. Ask early whether your home oncologist can give the drug after the first cycles in Germany, and how side effects will be reported.

Questions to Ask Your Oncologist

Is immunotherapy recommended for my cancer and stage, and what evidence supports it?
What do my biomarker results (PD-L1, MSI and others) mean for my treatment?
Which drug or combination do you recommend, and is it approved by the EMA for my cancer?
How long will treatment last, and how often will I have scans?
Can I continue treatment at home?
What side effects should I watch for, and who do I contact if they occur?
Am I eligible for any clinical trials?
What does the cost estimate include and exclude?

Recovery and Follow-Up

During treatment. Blood tests before each cycle, and scans every 2 to 3 months to check response.
Side effects. Report diarrhoea, cough, breathlessness, rash, extreme tiredness or unusual headaches promptly, even after treatment has ended.
After treatment. Regular follow-up scans and blood tests, including thyroid and hormone checks.
Shared care. Follow-up is usually shared between the German centre and your oncologist at home.

How Vaidam Helps International Patients?

Vaidam Health is a medical travel facilitation service. It does not provide medical treatment itself. When you contact Vaidam, you are assigned a case manager who can:

share your records and scans with German cancer centres for a second opinion and treatment plan
obtain a medical opinion and written cost estimate, usually within 48 hours
help you compare hospitals against the criteria above
help with visa documentation and the hospital's invitation letter
arrange accommodation near the hospital, airport transfers and appointment scheduling
arrange interpreters (in Germany, interpreter services are chargeable)
stay in contact after you return home to help with follow-up consultations and reports

Vaidam states that its services are free for patients and do not increase the hospital bill. Treatment decisions remain with your doctors.

Frequently Asked Questions

1. Which cancers can be treated with immunotherapy in Germany?

Approved immunotherapies are used for melanoma, lung, kidney, bladder, head and neck, triple-negative breast, liver and cervical cancers, cancers with mismatch repair deficiency, and several blood cancers. Suitability depends on stage and biomarkers.

2. Is immunotherapy suitable for every cancer patient?

No. Many cancers, such as most pancreatic and prostate cancers, respond poorly. Patients with some autoimmune diseases or those who have had organ transplants may face higher risks. Your oncologist will decide based on your cancer, biomarkers and health.

3. How is immunotherapy given?

Checkpoint inhibitors are given as a drip into a vein, usually every 3 to 6 weeks, in a day clinic. CAR-T cells are a single infusion after weeks of preparation. Bispecific antibodies start in hospitals.

4. How long does immunotherapy last?

Checkpoint inhibitors are often given for 1 to 2 years, or for a set number of cycles around surgery. Treatment stops earlier if the cancer grows or side effects are severe.

5. How much does immunotherapy cost in Germany?

The German price for pembrolizumab is about €4,080 per standard dose, or about €69,300 for a year of the drug alone. Hospital charges, scans and tests add to this. Per-cycle prices vary widely, so ask for an itemised estimate.

6. What is the success rate of immunotherapy?

It depends on the cancer. In advanced melanoma, 43% of patients treated with nivolumab plus ipilimumab were alive at 10 years. In advanced lung cancer with high PD-L1, 31.9% treated with pembrolizumab were alive at 5 years. Many patients do not respond.

7. What are the side effects?

Immune-related side effects can affect the skin, bowel, hormone glands, lungs and liver. Most are mild and treatable with corticosteroids. Some hormone problems are permanent.

8. Is dendritic cell therapy an approved treatment in Germany?

No, dendritic cell therapy is currently not approved in the EU. The EMA warned patients in 2025 against unregulated dendritic cell therapies, including those offered by some German clinics under national rules.

9. Can I continue immunotherapy at home after starting in Germany?

Often, yes. Many patients have the first cycles in Germany and continue with their home oncologist under a plan agreed with the German team, if the drug is available in their country.

10. How can international patients access immunotherapy in Germany?

Send your pathology, biomarker results, scans and treatment history for a second opinion. The hospital will advise whether immunotherapy is suitable and provide a written cost estimate.

Sources

Pharmaceutical Technology: unsafe and unregulated cell therapies being sold in Europe (EMA warning on dendritic cell therapies, 14 March 2025).
Paul-Ehrlich-Institut: Vorsicht bei kommerziellen Behandlungsangeboten mit nicht zugelassenen ATMP (31 March 2025).
European Commission decision on the withdrawal of the Provenge marketing authorisation (6 May 2015).
Pharmazeutische Zeitung: Blockbuster Keytruda als Systemsprenger (Keytruda price per 100 mg in Germany).
Targeted Oncology: 10-year data from CheckMate 067 (Wolchok et al., NEJM 2024).
Merck and Journal of Clinical Oncology: KEYNOTE-024 five-year outcomes (Reck et al., 2021).
Amgen: European Commission approval of Imlygic (December 2015).
Thoraxklinik Heidelberg; Charité – Universitätsmedizin Berlin; Heidelberg University Hospital (CAR-T); University Hospital Würzburg (100th CAR-T patient, March 2023).
Bookimed: Keytruda immunotherapy in Germany (accessed October 2026).
Booking Health: immunotherapy for lung cancer in Germany (29 June 2026).
Vaidam.com homepage (service descriptions).